Stoke Therapeutics
STOK
24.29
-0.08
-0.33%
Stoke Therapeutics
US · STOK
#2942 by market cap
Listed 2019
24.29
-0.08
-0.33%
Live - 5344 symbols - heartbeat 335s ago
· 2026-10-08 07:31
Pre-market
23.50
-3.25%
After-hours
24.29
0.00%
- Market cap
- 1.57B
- P/E (TTM)i
- -7.25
- P/Bi
- 4.54
- EPSi
- -0.12
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on STOK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 13.58, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +404.50% YoY
Margins
- Operating margin
- -11.16%
- Net margin
- -3.73%
Key ratios & quality
- Altman Z-Scorei
- 13.58
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.41M | 11.91M | 20.85M | 31.90M | 38.92M | 41.32M | 48.79M | 67.09M |
| Research & development | 8.37M | 23.76M | 32.20M | 54.17M | 77.84M | 82.23M | 89.13M | 137.92M |
| Operating profit | -12.78M | -35.68M | -53.04M | -86.07M | -104.36M | -114.77M | -101.37M | -20.59M |
| Pretax profit | -12.52M | -32.33M | -52.24M | -85.81M | -101.07M | -104.70M | -88.98M | -6.89M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -12.52M | -32.33M | -52.24M | -85.81M | -101.07M | -104.70M | -88.98M | -6.89M |
| Basic EPS | -1 | -2 | -2 | -2 | -3 | -2 | -2 | 0 |
| Diluted EPS | -0.53 | -1.80 | -1.56 | -2.34 | -2.60 | -2.38 | -1.65 | -0.12 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 158.57M | 13.82M | 10.63M | 1.40M | 6.23M | 9.33M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 14.65M | 15.26M | 16.03M | 21.15M | 19.97M | 25.25M |
| Research & development | 32.68M | 25.86M | 37.70M | 41.70M | 39.67M | 49.50M |
| Operating profit | 111.24M | -27.30M | -43.09M | -61.44M | -53.42M | -65.43M |
| Pretax profit | 114.16M | -23.48M | -39.63M | -57.93M | -50.00M | -61.62M |
| Tax | 1.28M | 0 | -1.28M | -- | 0 | 0 |
| Net profit | 112.88M | -23.48M | -38.35M | -57.93M | -50.00M | -61.62M |
| Basic EPS | 2 | 0 | -1 | -1 | -1 | -1 |
| Diluted EPS | 1.90 | -0.40 | -0.65 | -1.00 | -0.79 | -0.93 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 106.14M | 226.03M | 293.93M | 229.22M | 244.07M | 215.34M | 232.76M | 305.70M |
| Cash & ST investments | 105.40M | 222.47M | 287.31M | 219.81M | 229.60M | 201.39M | 216.90M | 284.67M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 107.54M | 228.75M | 297.93M | 238.87M | 256.07M | 228.34M | 271.56M | 418.43M |
| Total current liabilities | 2.47M | 4.10M | 11.43M | 17.14M | 31.39M | 30.82M | 40.06M | 57.88M |
| Short-term debt | -- | -- | 1.07M | 1.51M | 2.36M | 2.06M | 2.32M | 3.01M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 2,471,000.00 | 4,322,000.00 | 11,847,000.00 | 21,088,000.00 | 71,218,000.00 | 68,777,000.00 | 42,534,000.00 | 65,977,000.00 |
| Total equity | 105.07M | 224.43M | 286.08M | 217.78M | 184.85M | 159.57M | 229.02M | 352.46M |
| Retained earnings | -25.71M | -58.04M | -110.28M | -196.08M | -297.15M | -401.85M | -490.83M | -497.72M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 375.74M | 269.97M | 272.44M | 305.70M | 366.68M | 322.54M |
| Cash & ST investments | 357.32M | 247.71M | 248.31M | 284.67M | 343.55M | 292.82M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 406.89M | 384.51M | 360.26M | 418.43M | 443.28M | 393.97M |
| Total current liabilities | 44.69M | 38.68M | 41.73M | 57.88M | 40.81M | 41.93M |
| Short-term debt | 2.35M | 2.30M | 2.91M | 3.01M | 2.43M | 1.85M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 56,814,000.00 | 49,565,000.00 | 52,159,000.00 | 65,977,000.00 | 48,400,000.00 | 48,419,000.00 |
| Total equity | 350.07M | 334.94M | 308.11M | 352.46M | 394.88M | 345.55M |
| Retained earnings | -377.95M | -401.43M | -439.78M | -497.72M | -547.72M | -609.34M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -10.96M | -31.06M | -42.22M | -66.91M | -31.87M | -81.07M | -86.85M | 45.59M |
| Depreciation & amortization | 214.00K | 450.00K | 888.00K | 974.00K | 1.55M | 2.47M | 2.18M | 1.77M |
| Free cash flow | -11.90M | -32.69M | -43.27M | -68.11M | -35.83M | -82.68M | -87.05M | 44.92M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 151.91M | 105.40M | 0 | 45.34M | 52.08M | 128.84M | 87.78M |
| Ending cash balance | 105.60M | 222.68M | 287.51M | 145.46M | 114.13M | 192.01M | 128.78M | 84.94M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 131.83M | -25.42M | -30.37M | -30.45M | -60.58M | -56.59M |
| Depreciation & amortization | 477.00K | 446.00K | 442.00K | 405.00K | 439.00K | 458.00K |
| Free cash flow | 131.68M | -25.58M | -30.50M | -30.69M | -60.94M | -58.56M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 87.78M | 80.66M | 0 |
| Ending cash balance | 275.61M | 102.27M | 84.12M | 84.94M | 159.38M | 113.73M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -24.13 | -19.62 | -20.47 | -34.06 | -50.20 | -60.80 | -45.80 | -2.37 |
| ROA %i | -22.77 | -19.22 | -19.84 | -31.97 | -40.84 | -43.23 | -35.60 | -2.00 |
| ROIC %i | -24.65 | -21.66 | -20.76 | -33.86 | -49.73 | -60.03 | -45.29 | -2.35 |
| 5-year avg ROE %i | -- | -- | -- | -- | -29.70 | -37.03 | -42.27 | -38.65 |
| EBIT margin %i | -- | -- | -- | -- | -841.24 | -1,307.21 | -277.31 | -11.16 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 24.35 |
| Current ratioi | 43.03 | 55.12 | 25.73 | 13.37 | 7.77 | 6.99 | 5.81 | 5.28 |
| Quick ratioi | 42.80 | 54.32 | 25.15 | 12.83 | 7.33 | 6.54 | 5.47 | 5.06 |
| Debt / assetsi | -- | -- | 0.36 | 0.63 | 0.92 | 0.90 | 0.86 | 0.72 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | 0.00 | 0.00 | -- | -- | -- | 145.89 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 20.50 | 18.17 | 15.02 | -2.37 | -45.58 | -61.10 |
| ROA %i | 16.43 | 15.16 | 12.41 | -2.00 | -39.94 | -53.41 |
| ROIC %i | 20.31 | 18.03 | 14.88 | -2.35 | -45.29 | -60.73 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 20.03 | 20.15 | 13.23 | -11.16 | -577.46 | -809.69 |
| FCF / sales %i | 36.25 | 30.59 | 25.47 | 24.35 | -- | -- |
| Current ratioi | 8.41 | 6.98 | 6.53 | 5.28 | 8.99 | 7.69 |
| Quick ratioi | 8.01 | 6.45 | 6.21 | 5.06 | 8.57 | 7.19 |
| Debt / assetsi | 0.58 | 0.60 | 0.81 | 0.72 | 0.55 | 0.47 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Stoke100.00%
Quote time 2026-10-08 07:31:22 · For reference only, not investment advice and not tailored to your situation.